---
author:
  - name: Ben Fidler
    url: 'http://www.xconomy.com/author/bfidler/'
    avatar: {}
related: []
publisher:
  url: 'http://www.xconomy.com'
  name: Xconomy
  favicon: 'http://www.xconomy.com/wordpress/wp-content/themes/xconomy/images/favicon.ico'
  domain: www.xconomy.com
keywords:
  - mersana
  - kadmon
  - therapeutics
  - biotech
  - editas
  - ma-based
  - nasdaq
  - gene
  - boston
  - therapies
description: 'Xconomy Boston - There was biotech news up and down the East Coast this week. In Boston, all eyes were on the first biotech IPO of the year-and the sector let out a collective sigh when things went well.'
inLanguage: en
app_links: []
isBasedOnUrl: 'http://www.xconomy.com/boston/2016/02/05/east-coast-bio-roundup-crispr-tessier-lavigne-pricing-spero-more/?utm_content=buffer8b179&utm_medium=social&utm_source=linkedin.com&utm_campaign=buffer'
title: Editas Medicine IPO
datePublished: '2016-02-16T05:25:17.411Z'
dateModified: '2016-02-16T05:23:57.212Z'
sourcePath: _posts/2016-02-16-editas-medicine-ipo.md
published: true
inFeed: true
hasPage: false
inNav: false
_context: 'http://schema.org'
_type: MediaObject

---
# Editas Medicine IPO

<article style=""><h1>East Coast Bio Roundup&amp;colon; CRISPR&amp;comma; Tessier-Lavigne&amp;comma; Pricing&amp;comma; Spero &amp; More &amp;vert; Xconomy</h1><p>Xconomy Boston - There was biotech news up and down the East Coast this week&amp;period; In Boston&amp;comma; all eyes were on the first biotech IPO of the year-and the sector let out a collective sigh when things went well&amp;period;</p><img src="http://www.xconomy.com/wordpress/wp-content/images/2016/02/8535190554_44be85c043_k_mini.jpg" /></article>